Literature DB >> 15234038

Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding.

Amy Mueller1, Kent Wallner, Gregory Merrick, Eric Ford, Steven Sutlief, William Cavanagh, Wayne Butler.   

Abstract

PURPOSE: To correlate rectal wall doses and perirectal seed numbers with late rectal bleeding after prostate brachytherapy. METHODS AND MATERIALS: We studied 148 patients randomized to implantation with I-125 vs. Pd-103 at the VA Puget Sound HCS from 1998 through 2001 and for whom postimplant dosimetry was available. Implants were performed by standard techniques, using a modified peripheral loading pattern. A postimplant computed tomography (CT) scan (3 mm slice thickness) was obtained 1-4 h after implantation. Rectal doses were expressed as the R100, R200, and R300, defined as the rectal volume (cc) that received more than 100%, 200%, or 300% of the prescription dose, respectively. The rectum was considered to be a solid structure defined by the outer wall, without attempting to differentiate the inner wall or contents. In addition to conventional dose parameters, each patient's postimplant CT scan was reviewed for the number of seeds within 0, 0.1-2, and 2.1-4 mm of the outer rectal wall. The proximal edge of the seed was used for distance determinations from the outer rectal wall. Patients who reported Grade 1 or higher Radiation Therapy Oncology Group morbidity were contacted by telephone to obtain more details regarding their rectal bleeding. Those who reported persistent bleeding lasting for more than 1 month were categorized as Grade 2.
RESULTS: Patients had a wide range of rectal wall doses, with R100 values ranging from 0.0 to 10.4 cc (median, 0.95 cc). Similarly, the number of perirectal seeds within 0.0 to 2.0 mm of the rectum varied widely, ranging from 0 to 12 seeds (median: 1 seed). Seven patients (7 of 144 = 5%) developed persistent rectal bleeding, one of whom required a colostomy. Both rectal radiation doses and the number of perirectal seeds were higher in patients with persistent rectal bleeding. The number of perirectal seeds < or =2.0 mm of the rectal wall was higher in patients with rectal bleeding (p = 0.037), but the number of seeds 2-4 mm from the wall were not related (p = 0.72). In multivariate regression analysis including prostatic D90 (the dose that covers 90% of the postimplant prostate), preimplant transrectal ultrasound volume, R300, and the number of seeds < or =2 mm from the rectal wall as independent variables, only the R300 was statistically significantly associated with the likelihood of persistent rectal bleeding (p = 0.025).
CONCLUSION: A limited number of errant perirectal sources in itself does not appear to place patients at increased risk of rectal bleeding, providing that the overall rectal wall doses are within acceptable values.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234038     DOI: 10.1016/j.ijrobp.2003.12.016

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

Review 1.  Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy.

Authors:  Scott G Williams; Anthony L Zietman
Journal:  World J Urol       Date:  2008-09-07       Impact factor: 4.226

2.  Evaluation of rectal bleeding factors associated with prostate brachytherapy.

Authors:  Manabu Aoki; Kenta Miki; Hiroshi Sasaki; Masato Kido; Jun Shirahama; Sayako Takagi; Masao Kobayashi; Chikara Honda; Chihiro Kanehira
Journal:  Jpn J Radiol       Date:  2009-12-25       Impact factor: 2.374

3.  Narrow safety range of intraoperative rectal irradiation exposure volume for avoiding bleeding after seed implant brachytherapy.

Authors:  Ryuji Nakamura; Koyo Kikuchi; Susumu Tanji; Tomonori Yabuuchi; Ikuko Uwano; Satoshi Yamaguchi; Hisanori Ariga; Tomoaki Fujioka
Journal:  Radiat Oncol       Date:  2012-01-31       Impact factor: 3.481

4.  Hemiablative Focal Low Dose Rate Brachytherapy: A Phase II Trial Protocol.

Authors:  Ana Fernandez Ots; Joseph Bucci; Yaw Sinn Chin; David Malouf; Andrew Howie; Komiti Ese Enari
Journal:  JMIR Res Protoc       Date:  2016-06-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.